Alaunos Therapeutics, Inc. — Revenue by Fiscal Year
11 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/67df41e6-e9c9-429f-90ef-5de9dc444bbd/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2025 | $5.0k | 2025-01-01 – 2025-12-31 | evidence 0001193125-26-134720 |
| FY 2024 | $10.0k | 2024-01-01 – 2024-12-31 | evidence 0000950170-25-047758 |
| FY 2023 | $5.0k | 2023-01-01 – 2023-12-31 | evidence 0000950170-24-038868 |
| FY 2022 | $2.9M | 2022-01-01 – 2022-12-31 | evidence 0000950170-23-006377 |
| FY 2021 | $398.0k | 2021-01-01 – 2021-12-31 | evidence 0000950170-22-004972 |
| FY 2020 | $0 | 2020-01-01 – 2020-12-31 | evidence 0000950170-22-004972 |
| FY 2018 | $146.0k | 2018-01-01 – 2018-12-31 | evidence 0001193125-19-063978 |
| FY 2017 | $6.4M | 2017-01-01 – 2017-12-31 | evidence 0001193125-19-063978 |
| FY 2016 | $6.9M | 2016-01-01 – 2016-12-31 | evidence 0001193125-19-063978 |
| FY 2012 | $800.0k | 2012-01-01 – 2012-12-31 | evidence 0001193125-13-112464 |
| FY 2011 | $867.0k | 2003-09-10 – 2012-03-31 | evidence 0001144204-12-025871 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Alaunos Therapeutics, Inc. — all facts · Net Income · Operating Income